Wikisage, the free encyclopedia of the second generation, is digital heritage

Diacomit: Difference between revisions

From Wikisage
Jump to navigation Jump to search
m ((R))
No edit summary
 
(7 intermediate revisions by the same user not shown)
Line 1: Line 1:
Diacomit <sup>®</sup>contains 250 mg stiripentol<ref>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf</ref><ref>A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. Arzneimittelforschung. 1984; 34(2):199-204.</ref>
Diacomit <sup>®</sup>contains 250 mg [[stiripentol]]<ref>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf</ref><ref>A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study. Arzneimittelforschung. 1984; 34(2):199-204.</ref>


<ref>[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2006.00497.x/pdf Stiripentol, a Putative Antiepileptic Drug, Enhances the Duration of Opening of GABA<sub>A</sub>-Receptor Channels]</ref>
<ref>[http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1167.2006.00497.x/pdf Stiripentol, a Putative Antiepileptic Drug, Enhances the Duration of Opening of GABA<sub>A</sub>-Receptor Channels]</ref>
Line 5: Line 5:




In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union
In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy ([[Dravet%27s_syndrome|Dravet's syndrome]]). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union
[[Dravet's syndrome]] does not exist data for combined therapy both valproic acid or [[clobazam]]<ref>Aras et al 2015</ref>
[[Dravet's syndrome]] does not exist data for combined therapy both [[valproic acid]] or [[clobazam]]<ref>[http://www.epilepsybehavior.com/article/S1525-5050(14)00698-2/pdf Aras et al 2015]</ref>


==ATC==
==ATC==
Line 12: Line 12:
http://www.whocc.no/atc_ddd_index/?code=N03AX17
http://www.whocc.no/atc_ddd_index/?code=N03AX17


<references/>
{{refs}}
 
[[Category:GABAA_receptor_positive_allosteric_modulators]]

Latest revision as of 23:36, 24 August 2020

Diacomit ®contains 250 mg stiripentol[1][2]

[3]


In December 2001 the European Medicines Agency (EMA) granted stiripentol orphan drug status (designation number EU/3/01/071) for the treatment of severe myoclonic epilepsy of infancy (Dravet's syndrome). On 4 January 2007, the EMA granted the drug a marketing authorisation that is valid throughout the European Union Dravet's syndrome does not exist data for combined therapy both valproic acid or clobazam[4]

ATC

http://www.whocc.no/atc_ddd_index/?code=N03AX17

References

References: